Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors

Circulation. 1992 Oct;86(4):1310-6. doi: 10.1161/01.cir.86.4.1310.

Abstract

Background: A brief period of myocardial ischemia can result in an increased resistance to subsequent, more severe episodes of ischemia. Recent studies have indicated that activation of adenosine A1-receptors may mediate this preconditioning effect. It is also known that A1-activation can lead to ATP-sensitive potassium channel (KATP) opening via a G(i) protein-mediated effect. Thus, we determined whether the KATP blocker glyburide could abolish preconditioning or the protective effects of A1-receptor activation.

Methods and results: Anesthetized dogs were subjected to 5 minutes of left circumflex coronary artery (LCx) occlusion (or sham) followed by 10 minutes of reperfusion. The hearts were then subjected to 60 minutes of LCx occlusion and 5 hours of reperfusion. Glyburide (5 micrograms/kg/min) or vehicle was given directly into the LCx 20 minutes before preconditioning or sham preconditioning. Preconditioning resulted in a significantly reduced infarct size compared with nonpreconditioned animals. Glyburide abolished the protective effect of preconditioning. To establish a link between KATP and A1-receptor activation, the effect of the A1-agonist R-PIA with or without glyburide on infarct size was determined. R-PIA (0.4 microgram/kg/min, directly into the LCx) significantly reduced infarct size, and this protective effect was abolished by glyburide. None of the treatments described above had a significant effect on peripheral hemodynamic status or myocardial blood flow.

Conclusions: Preconditioning may be mediated by KATP activation, and this may be linked to A1-receptor stimulation.

MeSH terms

  • Adaptation, Physiological* / drug effects
  • Adenosine Triphosphate / pharmacology*
  • Animals
  • Coronary Disease / physiopathology
  • Dogs
  • Female
  • Heart / drug effects
  • Heart / physiopathology*
  • Male
  • Myocardial Reperfusion
  • Myocardium / metabolism*
  • Phenylisopropyladenosine / pharmacology
  • Potassium Channels / drug effects
  • Potassium Channels / physiology*
  • Purinergic Antagonists
  • Receptors, Purinergic / physiology*

Substances

  • Potassium Channels
  • Purinergic Antagonists
  • Receptors, Purinergic
  • Phenylisopropyladenosine
  • Adenosine Triphosphate